Vanessa Research (VR) – a Connecticut-based biomedical company discovering, developing, and commercializing innovative products in areas of unmet medical needs – announced the appointment of A. Donald Janezic, CPA, CGMA as Chief Financial Officer, effective June 1, 2019. Janezic joins as a key member of the expanding company’s executive leadership team, and as a visionary strategist expected to drive the international success of VR’s brand portfolio.
Janezic is a graduate of Bentley University (BSA, 1978) and the University of New Haven (MBA, 1983). He is a Certified Public Accountant and an active member of the Connecticut Society of CPAs (CTCPA) along with a myriad of other professional organizations. Previously, he served as a senior accountant for KPMG, and a law firm administrator for MCRP, both in Hartford CT. He was also CFO for two manufacturing companies, most recently Bigelow Tea of Fairfield CT where he retired after 30 years of service.
Along with his influential management position, Janezic is a member of the Vanessa Board of Directors and will lead all financial activity of VR’s international operations as CFO.
Commenting on his appointment, Janezic stated: “Joining the executive team at Vanessa Research is both exciting and challenging as we take the company from unique product research and development to actual production and distribution on an international scale. The acquisition of the GMP-certified pharmaceutical manufacturing facilities in Hungary will further permit Vanessa Research to fulfill its mission to ‘give hope where none existed’ – our promise to the world.”
About Vanessa Research
Vanessa Research (VR) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. VR’s continually-expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship products, Shylicine® and Hunazine® are the first-ever drug developed to treat the rare, lethal microvillus inclusion disease and a treatment designed to neutralize the cholera toxin, respectively.
VR is based in Hamden, Connecticut, with offices in Farmington, Connecticut; London, England; Budapest, Győr, and Kaposvár, Hungary; and Navarre, Spain.
Director of Marketing and Communications